Physician profile
Joshua S Hundert
NPI 1679732317
$229,209.31
in general payments reported to CMS, 2019-2025
18 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $6,881 · 2022: $46K · 2023: $8,830 · 2024: $72K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Travel and Lodging: $19K · Food and Beverage: $5,759 · Consulting Fee: $5,720 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,714.26 |
| Travel and Lodging | $18,977.58 |
| Food and Beverage | $5,758.77 |
| Consulting Fee | $5,720.00 |
| Education | $108.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $203,801.39 | 2021-2025 | |
| Novo Nordisk INC | $12,719.88 | 2024-2025 | Ozempic |
| Akebia Therapeutics INC | $7,310.17 | 2019-2024 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $4,069.53 | 2022-2025 | Tarpeyo |
| Nxstage Medical, INC. | $279.17 | 2023 | Nxstage System One, Pureflow Sl, Nxstage Cartridge Express |
| Amgen INC. | $217.56 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $208.44 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $149.67 | 2025 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $147.96 | 2023-2025 | |
| Travere Therapeutics, INC. | $88.83 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.75 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $41.21 | 2024-2025 | Farxiga |
| Baxter Healthcare | $29.87 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.71 | 2025 | Onpattro |
| Vifor Pharma, INC. | $24.78 | 2023 | Veltassa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Lilly USA, LLC | $18.14 | 2024 | Zepbound |
| Ardelyx, INC. | $14.56 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Hundert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.